Announced Tue, 23 Jun · 16:13 IST
Eris Lifesciences corporate presentation: FY26 results, FY27 guidance and Semaglutide launch
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.1%1-day move
₹1461.50
prior close
₹1474.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.4-0.4-0.6-0.1-4.1-1.7-0.8-0.9-1.3+1.2-4.4——
Up moveDown movePending
AI summary
Eris Lifesciences filed its June 2026 corporate presentation. FY26 revenue rose to Rs 3,129 cr (from Rs 2,894 cr) with EBITDA margin at 36%, expanding 400 bps since FY23. The company guided FY27 domestic growth at 1.3x market growth with 37% EBITDA margin, and international revenue growth of 18-20%. New Gx Semaglutide brand Sundae ranked #1 by sale volume in month one. EU-GMP inspection received procedural observations with minimal impact on existing business but delayed EU-CDMO product launches.
Likely market impact
Positive on FY27 margin guidance and strong Semaglutide launch; EU-CDMO delay is a near-term watchpoint.